In Q1 2026, DexCom demonstrated resilient revenue growth despite typical seasonal softening due to U.S. insurance deductible resets, driven by robust sensor sales and expanding customer adoption. The company’s core business model centers on recurring disposable sensor sales paired with reusable hardware, leveraging technological leadership in continuous glucose monitoring systems such as the G7 and Stelo biosensor. DexCom maintains a commanding competitive stance supported by early FDA approvals, integrated sales channels, and data-driven product innovation while actively pursuing growth beyond insulin-dependent diabetes. Key risks include intensifying competition, regulatory complexities, and supply chain management. Near-term milestones to watch include reimbursement trends for new product lines and expansion of CGM use into broader metabolic health applications.